Autobahn Therapeutics Presents Positive Phase 1 Results for ABX-002 at ASCP Annual Meeting

Autobahn Therapeutics announced positive Phase 1 clinical trial results for ABX-002, a novel thyroid hormone beta receptor (TRβ) selective agonist, at...
Home/KnloSights/Clinical Trial Updates/Autobahn Therapeutics Presents Positive Phase 1 Results for ABX-002 at ASCP Annual Meeting